Comparative Pharmacology
Head-to-head clinical analysis: BRIUMVI versus LEQEMBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIUMVI versus LEQEMBI.
BRIUMVI vs LEQEMBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.
Lecanemab is a humanized monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.
10 mg/kg intravenously every 2 weeks, administered over approximately 1 hour.
None Documented
None Documented
Terminal elimination half-life is approximately 19-20 days (range 11-30 days) in patients with relapsing multiple sclerosis. The long half-life supports every-6-month dosing.
Terminal half-life approximately 7.6 days (range 5-12 days) after multiple doses; supports monthly dosing.
BRIUMVI (ublituximab) is a monoclonal antibody. Elimination occurs via intracellular catabolism and is not excreted renally or fecally in significant amounts. No specific excretion data available.
Primarily catabolized to amino acids; not excreted renally or hepatically in unchanged form.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody